Current Report Filing (8-k)
February 13 2020 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 13,
2020
Edesa Biotech, Inc.
(Exact Name of Registrant as Specified in its Charter)
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State
or Other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6
(Address of
Principal Executive Offices)
(289) 800-9600
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐
Soliciting
material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
Common
Shares
|
|
EDSA
|
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 2.02
Results of Operations and Financial Condition.
On
February 13, 2020, Edesa Biotech, Inc. (the “Company”)
issued a press release announcing its financial results for the
three-month period ended December 31, 2019 (the “Earnings
Release”). The full text of the Earnings Release is attached
hereto as Exhibit 99.1. The information furnished herein and
therein shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”) or otherwise subject to the liabilities
of that Section, or incorporated by reference in any filing under
the Exchange Act or the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such a
filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
|
|
|
|
|
Press
release issued by Edesa Biotech, Inc. dated February 13,
2020.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Edesa
Biotech, Inc.
|
|
|
|
Date:
February 13, 2020
|
By:
|
/s/
Kathi Niffenegger
|
|
Name:
|
Kathi
Niffenegger
|
|
Title:
|
Chief
Financial Officer
|
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Sep 2023 to Sep 2024